NCT01400815已完成2 期
A Prospective, Double-blind, Randomized, Active Controlled, Parallel Group, Multicenter Phase II Clinical Trial to Evaluate the Effectiveness of X-22 as a Smoking Cessation Aid
22nd Century Limited, LLC3 个研究点 分布在 1 个国家目标入组 234 人开始时间: 2011年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 234
- 试验地点
- 3
- 主要终点
- Efficacy - 4 Weeks of Continuous Abstinence From Smoking Cigarettes
研究概览
简要总结
A randomized, active controlled clinical trial in which a total of 216 healthy smokers will be enrolled and followed over approximately 19 weeks.
The trial will evaluate the efficacy and safety of using X-22 as a smoking cessation aid.
Healthy smokers who plan to quit smoking will be screened for eligibility. Subjects will be randomized in a 1:1 ratio to 1 of the 2 treatment arms:
- Group 1: X-22 Cigarettes (very low nicotine)
- Group 2: Active Control Cigarettes The randomization will be stratified by gender. Efficacy will be assessed by analysis of cigarette consumption using self-report diaries and measurement of exhaled carbon monoxide (CO) and cotinine concentrations.
Safety will be assessed by evaluation of adverse events, physical examinations, clinical laboratory tests, and measurement of heart rate, blood pressure, and body weight at each study visit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must meet all of the following inclusion criteria to be eligible for participation in this study.
- •Subjects must be considered by the investigator to be in general good health and between 18 and 65 years of age, inclusive.
- •Subjects must have a history of smoking at least 10 cigarettes per day for at least 1 year, with less than 3 months of abstinence during the past year, and a continuous smoking history for at least 3 months prior to study entry.
- •Subjects must indicate that they plan to quit smoking within the next 3 months.
- •Subjects must have a CO measurement of ≥ 10 ppm at screening and baseline (Visit 1 and Visit 2).
- •Subjects must be willing and able to return for scheduled follow-up examinations for a total of 5 months.
- •Female subjects must have been postmenopausal for the previous 6 months or be surgically sterile, or must have a negative pregnancy test and use one of the following acceptable methods of birth control for the duration of the study and for at least 3 months prior to screening:
- •abstinence, meaning a total lack of sexual activity,
- •oral contraceptives ("the pill"),
- •contraceptive injections,
- •intrauterine device,
- •double-barrier method (diaphragm or condom plus spermicidal cream),
- •contraceptive patch, hormonal implant, hormonal vaginal ring, or
- •male partner sterilization at least 3 months prior to screening.
- •Subjects must sign and be given a copy of the written Informed Consent form.
- •Subjects must be able to read, understand and complete the questionnaires independently.
排除标准
- •Subjects who meet any of the following exclusion criteria are not to be enrolled in this study.
- •Subjects who have a household member who is already enrolled in this trial.
- •Subjects who have attempted to quit smoking using one or more FDA-approved smoking cessation products (eg, nicotine replacement therapy [NRT] including nicotine gum, nicotine lozenges, nicotine patches, nicotine nasal spray, or nicotine inhaler; Zyban [bupropion]; or Chantix [varenicline]) for longer than 1 week in the past 3 months.
- •Subjects who have been enrolled in another structured smoking cessation program (e.g., behavioral modification, hypnosis, acupuncture, or other alternative therapies) in the last 30 days.
- •Subjects who have been in another smoking cessation trial in the past 6 months.
- •Subjects who regularly use (greater than once per month) tobacco-based products other than cigarettes (eg, chew, snuff, snus, shisha, etc.).
- •Subjects with a history of coronary artery disease, myocardial infarction, stroke, chronic obstructive pulmonary disease, or other significant pulmonary diseases. Controlled hypertensive subjects and mild asthmatics whose disease is controlled only with an as-needed inhaled beta agonist are acceptable.
- •Subjects with a history of cancer within the past 60 months other than basal cell carcinoma.
- •Subjects with a history of thromboembolic disease or taking warfin or any other anticoagulant, or anti-platelet drug such as clopidogrel (Plavix®) or pentoxifylline (Trental®). Low dose aspirin therapy is acceptable.
- •Subjects with screening laboratory abnormalities that are considered by the investigator to be clinically significant.
- •Subjects with a body mass index (BMI) >
- •Subjects with poorly controlled diabetes or insulin-dependent diabetes.
- •Subjects with other known serious pathophysiology or topical or systemic disorders of any kind that would confound the results of the study.
- •Subjects with screening ECG abnormalities that are considered by the investigator to be clinically significant.
- •Subjects who have used any illegal drug in the past 3 months.
- •Subjects who have a positive urine drug screening result.
- •Subjects who are pregnant or lactating, or who plan to become pregnant during the course of the study.
- •Subjects participating in any other clinical trial of an investigational drug or device during the time of this clinical investigation or within 30 days prior to Screening visit.
- •Subjects taking anti-depressants, anti-psychotics, clonidine, or any of the classes of drugs listed in the RapidCHECK® 12 Panel in the last 60 days (see Section 12.1.1).
- •Subjects with systolic blood pressure over 140 mmHg and/or diastolic blood pressure over 90 mmHg.
- •Subjects consuming an average of 3 or more drinks of alcohol per day.
- •Subjects consuming greater than an average of 2 packs of cigarettes per day.
研究组 & 干预措施
Active Control Cigarette
Active Comparator
The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional "light" cigarette.
干预措施: Active Control Cigarettes (Drug)
X-22 Smoking Cessation Product
Experimental
The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.
干预措施: X-22 Smoking Cessation Product (Drug)
结局指标
主要结局
Efficacy - 4 Weeks of Continuous Abstinence From Smoking Cigarettes
时间窗: Weeks 7 and 9 = telephone call, Week 8 = visit 6 and Week 10 = visit 7
The primary efficacy measurement is the number of subjects with 4 weeks of continuous abstinence from smoking cigarettes (Weeks 7-10), as assessed by subject diary and confirmed by exhaled carbon monoxide (CO), after treatment termination, at Visits 6 and 7. A responder: did not smoke and had less than 10 ppm exhaled CO.
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
进行中（未招募）
不适用
A randomized, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution delivered by the Respimat® Inhaler with Tiotropium inhalation capsules 18 µg delivered by the HandiHaler®. - TIOSPIRChronic obstructive pulmonary disease (COPD)MedDRA version: 14.1Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2009-015713-51-SEBoehringer Ingelheim AB16,800
进行中（未招募）
不适用
A randomized, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution delivered by the Respimat® Inhaler with Tiotropium inhalation capsules 18 µg delivered by the HandiHaler®.Chronic obstructive pulmonary disease (COPD)MedDRA version: 12.1Level: LLTClassification code 10009033Term: <Manually entered code. Term in E.1.1>EUCTR2009-015713-51-PTBoehringer Ingelheim Pharmaceuticals, Inc16,800
已完成
3 期
A randomized, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution delivered by the Respimat® Inhaler with Tiotropium inhalation capsules 18 µg delivered by the HandiHaler®.chronic obstructive pulmonary diseaseCOPD10038716NL-OMON36382Boehringer Ingelheim150
进行中（未招募）
不适用
A randomized, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution delivered by the Respimat® Inhaler with Tiotropium inhalation capsules 18 µg delivered by the HandiHaler®. - TIOSPIRChronic obstructive pulmonary disease (COPD)MedDRA version: 12.1Level: LLTClassification code 10009033Term: <Manually entered code. Term in E.1.1>EUCTR2009-015713-51-LTBoehringer Ingelheim RCV GmbH & Co KG16,800
进行中（未招募）
1 期
A randomized, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution delivered by the Respimat® Inhaler with Tiotropium inhalation capsules 18 µg delivered by the HandiHaler®.EUCTR2009-015713-51-GBBoehringer Ingelheim Limited16,800